Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Talha Badar

Leukemia Attending

Mayo Clinic Florida

United States

Research Interests

Explore related searches

Professors in United States Professors in Biostatistics Biostatistics professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (8)

Farrukh T. Awan

University of Texas Southwestern Medical Center

UNITED STATES

View details

Aniko Szabo

UNITED STATES

View details

Chenyu Lin

Assistant Professor of Medicine

Duke University

UNITED STATES

View details

Shyam Patel

Assistant Professor

University of Massachusetts Chan Medical School

UNITED STATES

View details

Muhammad Bilal Abid

Texas Tech University Health Sciences Center

UNITED STATES

View details

Omer Jamy

The University of Alabama

UNITED STATES

View details

Veronika Bachanova

Faculty, Professor

University of Minnesota

UNITED STATES

View details

Soyoung Kim

Associate Professor

Medical College of Wisconsin

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Talha Badar

Research Interests

Explore related searches

Articles (20)

Menin Inhibitors in Acute Myeloid Leukemia: Clinical Integration, Resistance, and the Path Beyond Monotherapy

Modern Concepts in Precision Targeting of Acute Myeloid Leukemia Based on Principles of Molecular Oncology

Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia

Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study

Rapid germ line testing with hair root bulb-derived DNA for hereditary predisposition and inherited marrow failure states

DDX41 variants in focus: germ line to donor-derived MN

Distinct advantages for risk scoring models in patients with clonal cytopenia of undetermined significance

Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas

Outcomes of hemophagocytic lymphohistiocytosis in acute myeloid leukemia: the 3-site Mayo Clinic experience

Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias

Post‐FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy

Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL

Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in <i>TP53</i>-mutated myelodysplastic syndromes.

Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study.

New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma

Navigating prognostic stratification and approach to TP53-mutated myeloid neoplasms.

Clinical and Prognostic Impact of Allelic Status in EZH2-Mutated Myeloid Neoplasms.

Malignancies after Chimeric Antigen Receptor T Cell Therapy

Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia.

Outcomes of older patients with TP53-mutated myeloid neoplasms.

Collaborators (8)

Farrukh T. Awan

Aniko Szabo

Chenyu Lin

Shyam Patel

Muhammad Bilal Abid

Omer Jamy

Veronika Bachanova

Soyoung Kim

Make your next move.

Talha Badar

Research Interests

Explore related searches

Articles (20)

Menin Inhibitors in Acute Myeloid Leukemia: Clinical Integration, Resistance, and the Path Beyond Monotherapy

Modern Concepts in Precision Targeting of Acute Myeloid Leukemia Based on Principles of Molecular Oncology

Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia

Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study

Rapid germ line testing with hair root bulb-derived DNA for hereditary predisposition and inherited marrow failure states

DDX41 variants in focus: germ line to donor-derived MN

Distinct advantages for risk scoring models in patients with clonal cytopenia of undetermined significance

Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas

Outcomes of hemophagocytic lymphohistiocytosis in acute myeloid leukemia: the 3-site Mayo Clinic experience

Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias

Post‐FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy

Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL

Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in &lt;i&gt;TP53&lt;/i&gt;-mutated myelodysplastic syndromes.

Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study.

New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma

Navigating prognostic stratification and approach to TP53-mutated myeloid neoplasms.

Clinical and Prognostic Impact of Allelic Status in EZH2-Mutated Myeloid Neoplasms.

Malignancies after Chimeric Antigen Receptor T Cell Therapy

Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia.

Outcomes of older patients with TP53-mutated myeloid neoplasms.

Collaborators (8)

Farrukh T. Awan

Aniko Szabo

Chenyu Lin

Shyam Patel

Muhammad Bilal Abid

Omer Jamy

Veronika Bachanova

Soyoung Kim

Make your next move.

Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in <i>TP53</i>-mutated myelodysplastic syndromes.